<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721368</url>
  </required_header>
  <id_info>
    <org_study_id>MT_PRT_MVD01</org_study_id>
    <nct_id>NCT02721368</nct_id>
  </id_info>
  <brief_title>Neuramis® Volume Lidocaine Treatment in Patients With Loss of Mid-face Volume</brief_title>
  <official_title>Clinical Study of Neuramis® Volume Lidocaine to Evaluate the Efficacy and Safety for Temporary Restoring the Mid-face Volume</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of Neuramis® Volume&#xD;
      Lidocaine, which is a biomaterial prosthesis and graft, with Juvederm® Voluma® with&#xD;
      Lidocaine, for the patients who need correction due to a moderate-to-severe volume loss in&#xD;
      the mid-facial region by inducing temporary volume restoration in mid-facial region. After&#xD;
      the pivotal study, extension study will be conducted to confirm long-term safety and&#xD;
      efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centered, randomized, double-blind, split-face clinical study on&#xD;
      investigational device. The subjects in this clinical trial receive application of the&#xD;
      investigational device on the right and left side of the mid-facial region (Neuramis® Volume&#xD;
      Lidocaine or Juvederm® Voluma® with Lidocaine). After the pivotal study, extension study will&#xD;
      be conducted to confirm long-term safety and efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2016</start_date>
  <completion_date type="Actual">September 11, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of subjects defined as improved by independent photograph evaluator according to the overall Mid-Face Volume Deficit Scale(MFVDS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>MFVDS 0- None, 1-Minimal, 2-Mild, 3-Moderate, 4-Significant, 5-Severe The lower score, the better condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of subjects defined as improved by independent photograph evaluator according to the overall Mid-Face Volume Deficit Scale(MFVDS)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Primary outcome for extension study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes in overall Mid-Face Volume Deficit Scale(MFVDS) at each visit</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects defined as improved by blinded investigators and the subjects according to the Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Investigational medical device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuramis® Volume Lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator medical device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Juvederm® Voluma® with Lidocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuramis® Volume Lidocaine</intervention_name>
    <description>hyaluronic acid filler</description>
    <arm_group_label>Investigational medical device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juvederm® Voluma® with Lidocaine</intervention_name>
    <description>hyaluronic acid filler</description>
    <arm_group_label>Comparator medical device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject aged between 35 and 65.&#xD;
&#xD;
          2. Mid-facial region symmetrical, severity greater than MFVDS moderate-to-severe level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have anticoagulant therapy, antiplatelet therapy, and non-steroidal&#xD;
             anti-inflammatory drugs&#xD;
&#xD;
          2. Those who have history of receiving the procedures which are considered to affect on&#xD;
             the assessment of this clinical trial.&#xD;
&#xD;
          3. Those who has thin skin in the mid-facial area&#xD;
&#xD;
          4. Those with hypersensitivity to sodium hyaluronate or lidocaine or amide type local&#xD;
             anesthetics&#xD;
&#xD;
        &lt;Extension Study&gt;&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Participated in the pivotal study and completed the end of study visit&#xD;
&#xD;
          2. Agreed not to receive any procedure or treatment that may have an effect on the&#xD;
             restoration of the mid-face volume while participating in the extension study&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Those who have following procedual history between completion of the pivotal study and&#xD;
             entry of extension study&#xD;
&#xD;
             - facial plastic surgery, tissue grafting or tissue augmentation using implant, thread&#xD;
             lifting&#xD;
&#xD;
          2. Subjects with asymmetric MVD(Mid-face volume deficit) or facial scar interfering with&#xD;
             accurate assessment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BeomJoon Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang Univ. Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-Ang Univ. Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-gu</state>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

